QuantAbundanceAbundância, quantificada.

Notícias

Apenas manchetes de alto sinal - eventos macro, resultados, M&A, regulatório. Listicles e clickbait de analistas filtrados por padrão. Atualizado a cada hora.

35,152 signal articles · 109 in last 24h · 178,699 total before filter · latest 31m ago

109last 24h

3128last 7d

511● bullish (7d)

313● bearish (7d)

227publishers

All Macro103 Earnings1820 M&A172 Regulatory23 Product26 Analyst28

✕ clear all filtersticker: GILDSentiment:bullish neutral bearish ✓ showing all (incl. clickbait)

Motley Fool74d agobearish

Gilead Sciences Has Snapped Out of Its Slump -- and 1 Catalyst Is Doing Most of the Heavy Lifting

Proactive74d agoneutral

Vivace Therapeutics names new CEO as it prepares Phase 3 trial for mesothelioma drug

GuruFocus.com75d agoneutral

Eli Lilly Is Pulling Away From the Rest of Healthcare

ABBV ABT AMGN GILD ISRG JNJ LLY UNH

Motley Fool75d agoneutral

3 Dividend Stocks to Hold for the Next 10 Years

StockStory75d agoneutral

3 Unprofitable Stocks with Questionable Fundamentals

Stocktwits76d agoneutral

GILD Stock Garners Retail Attention On Trodelvy EU Approval Ahead Of August 27 HIV FDA Verdict

Trefis76d agoneutral

Exelixis Owners Keep Getting A Bigger Slice Of A Company In Transition

AMGN BMY GILD MRK PFE

Insider Monkey77d agoneutral

Gilead’s Core Business Is Accelerating, But Will Its $11 Billion Pipeline Bet Pay Off?

Insider Monkey77d agoneutral

Gilead’s HIV Business is Surging, but is the Company Too Dependent on One Franchise?

Insider Monkey77d agoneutral

Gilead’s Revenue Is Accelerating, But are its Acquisitions Worth the Cost?

Insider Monkey77d agoneutral

Pfizer vs. Gilead: Which Drugmaker Has the Stronger Growth Story?

Investor's Business Daily79d agoneutral

Making Drugs With AI: Biopharma Giants Gear Up For New Arena

AMGN GILD GOOG GOOGL TEM

Simply Wall St.80d agoneutral

Does Gilead (GILD) Pairing With Nucleai Reveal a Deeper Shift in Its Oncology Strategy?

Motley Fool81d agoneutral

Worried About a Market Crash? These 3 Stocks Beat the S&P 500 in 2008 and 2022

GILD MCD NVDA WMT ^GSPC

Barrons.com81d agobullish

Biotech Stocks Are Booming. What This Top Fund Is Buying Now.

Zacks82d agoneutral

Is Gilead's Expanding HIV Portfolio a Growth Catalyst?

Motley Fool82d agoneutral

Gilead Sciences Has Quietly Become One of the Most Underrated Turnaround Stories in Healthcare. Here's Why Wall Street Is Excited.

TheStreet83d agoneutral

Gilead yanks out a thorn in its side in major court ruling

StockStory84d agoneutral

Gilead Sciences (GILD): Buy, Sell, or Hold Post Q2 Earnings?

Insider Monkey86d agoneutral

Can MacroGenics (MGNX) Turn Gilead Sciences (GILD)’s $10M Milestone Into a Major Pipeline Catalyst?

Quartz86d agobullish

Gilead wins appeals court ruling against overseas drug imports

TheStreet86d agobullish

BofA biotech scorecard: Two buys and odd one out

AMGN BAC GILD VRTX

Insider Monkey87d agobullish

Could Merck & Co., Inc. (MRK) and Gilead Sciences, Inc. (GILD)’s Partnership Create the Next Big Pharma Growth Engine

Simply Wall St.87d agoneutral

Gilead (GILD) Stock Still Looks Cheap On Sales Despite A 127% Run

Simply Wall St.87d agoneutral

Why Gilead Sciences (GILD) Is Back In The Spotlight

StockStory88d agoneutral

5 Must-Read Analyst Questions From Gilead Sciences’s Q2 Earnings Call

Simply Wall St.88d agoneutral

Gilead Sciences (GILD) Expands ADC Research With AI Tissue Analytics

Zacks88d agobearish

TNGX Stock Dips 5% as Q2 Earnings Miss Estimates on Higher Expenses

StockStory89d agoneutral

3 Healthcare Stocks with Open Questions

MoneyShow91d agoneutral

GILD- An Attractive Biotech Stock with Solid Base Revenue Growth